Top

Published in:

Open Access 01-05-2014 | Review Article

Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma

Authors: Lidia Gil, Maciej Kazmierczak, Renata Kroll-Balcerzak, Mieczyslaw Komarnicki

Published in: Medical Oncology | Issue 5/2014

Abstract

Recently, bendamustine has become an important agent in the treatment for patients with lymphoid malignancies. Although the drug has received approval for second-line therapy in indolent lymphoma, a growing body of evidence suggests its efficacy and safety in first-line use. The results of randomised and observational studies with bendamustine as front-line therapy in non-Hodgkin lymphoma (NHL) with emphasis on efficacy and toxicity are presented. Furthermore, completed and ongoing clinical trials evaluating upfront bendamustine effectiveness in combination with other agents are discussed. The review refers mainly to indolent lymphoma, mantle cell lymphoma and aggressive lymphoma, as the most commonly diagnosed NHL types. Finally, we elaborated on the safety profile of bendamustine and the perspectives of using the drug as a first-line therapy.

Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, Elliott G, Niemeyer CC. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008;14:309–17.PubMedCrossRef

Gandhi V. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Semin Oncol. 2002;29:4–11.PubMedCrossRef

Chow KU, Boehrer S, Geduldig K, Krapohl A, Hoelzer D, Mitrou PS, Weidmann E. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin’s lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica. 2001;86:485–93.PubMed

Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, van der Jagt RH, Cheson BD. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer. 2010;116:106–14.PubMedCentralPubMed

Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS, Fayad LE, Bessudo A, Camacho ES, Williams ME, van der Jagt RH, Oliver JW, Cheson BD. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol. 2008;26:204–10.PubMedCrossRef

Kahl B. Chemotherapy combinations with monoclonal antibodies in non-Hodgkin’s lymphoma. Semin Hematol. 2008;45:90–4.PubMedCentralPubMedCrossRef

Knauf WU, Abenhardt W, Nusch A, Grugel A, Marschner N. Bendamustine-rituximab (BR) replaces R-CHOP as “standard of care” in the treatment of indolent non-Hodgkin lymphoma in German Hematology Outpatient Centers. Blood. 2012; 120: Abstract 3666.

Herold M, Schulze A, Niederwieser D, Franke A, Fricke HJ, Richter P, Freund M, Ismer B, Dachselt K, Boewer C, Schirmer V, Weniger J, Pasold R, Winkelmann C, Klinkenstein C, Schulze M, Arzberger H, Bremer K, Hahnfeld S, Schwarzer A, Muller C. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol. 2006;132:105–12.PubMedCrossRef

Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Durk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203–10.PubMedCrossRef

10.

Flinn IW, Richard H, Van der Jagt, Kahl B. An open-label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line treatment of patients with advanced indolent non-Hodgkin’s lymphoma (NHL) or mantle cell lymphoma (MCL). The bright study. Blood. 2012; 120: Abstract 902.

11.

van der Jagt R. Bendamustine for indolent non-Hodgkin lymphoma in the front-line or relapsed setting: a review of pharmacokinetics and clinical trial outcomes. Expert Rev Hematol. 2013;6:525–37.PubMedCrossRef

12.

Rummel MJ, Lerchenmuller C, Greil R, Gorner M, Hensel M, Engel E, Jaeger U, Breuer F. Bendamustin-rituximab induction followed by observation or rituximab maintenance for newly diagnosed patients with waldenstrom macroglobulinemia: results from prospective, randomized, multicenter study (StiL NHL 7-2008—MAINTAIN). Blood. 2012;120:2739.

13.

Salar A, Doningo-Domenech E, Panizo C, Nicolas C, Bargay J, Muntanola A, Canales M. Final results of a multicenter phase II trial with bendamustine and rituximab as first line treatment for patients with MALT lymphoma. Blood. 2012;120:Abstract 3691.

14.

Luminari S, Goldaniga MC, Cesaretti M, Orsucci L, Tucci A, Pulsoni A, Salvi F. Bendamustine and rituximab combination in untreated indolent non follicular B-cell non-Hodgkin’s lymphoma. A phase II study from the Fondazione Italiana Linfomi. Blood. 2013;122:Abstract 3049.

15.

Flinn IW, Thompson DS, Boccia RV, Miletello G, Lipman A, Flora D, Cuevas D. Bendamustine, bortezomib, and rituximab, in patients with previously untreated low grade lymphoma: A phase II Trial of the Sarah Cannon Research Institute. Blood. 2012;120:Abstract 1624.

16.

Boccomini C, Ladetto M, Rigacci L, Arcaini L, Ceccarelli M, Lobetti-Bodoni C, Volpetti S. Breif chemoimmunotherapy rituximab, bendamustine, mitoxantrone (R-BM) Followed by RITUXIMAB Consolidation in elderly patients with untreated advanced stage follicular lymphoma (FL): preliminary results of prospective phase II study by Fondazione Italiana Linfomi. Blood. 2012;120:Abstract 2720.

17.

Fowler NH, Kahanic SP, Forero A, Munteanu MC, Davis GL, Brown P. Results of a Phase II Study with Bendamustine and Ofatumumab in Untreated Indolent B-cell Non-Hodgkin’s Lymphoma. Blood. 2011;118:Abstract 778.

18.

Martinez-Chamorro C, Pinizo C, Quero C, Deben G, Paz J, Batlle A, Serrano A. Bendamustine in combination with rituximab as first-line treatment for indolent non-Hodgkin lymphoma: retrospective analysis of a Spanish Registry. Blood. 2013;122:5094.

19.

Visco C, Finotto S, Zambello R, Paolini R, Menin A, Zanotti R, Zaja F, Semenzato G, Pizzolo G, D’Amore ES, Rodeghiero F. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol. 2013;31:1442–9.PubMedCrossRef

20.

Magni M, Di Nicola M, Carlo-Stella C, Devizzi L, Guidetti A, Matteucci P. Safety, tolerability and activity of ofatumumab, bendamustine and dexamethasone combination as first-line treatment of mante-cell lymphoma in the elderly: a multicenter study. Blood. 2011;118:Abstract 1647.

21.

Jerkeman M, Albertsson-Lindblad A, Kolstad A, Laurell A, Raty R, Grrnbck K. Lenalidomide, bendamustine, and rituximab as firs-line therapy for patients > 65 years with mantle cell lymphoma: preliminary results from the nordic lymphoma group MCL4 Phase I-II Trial. Blood. 2013;122:Abstract 4377.

22.

Gressin R, Callanan M, Daguindau N, Tempescul A, Carras S, Cartron G. The ribvd regimen (rituximab IV, bendamustine IV, velcade SC, dexamethasone IV) offers a high complete response rate in elderly patients with untreated mantle cell lymphoma. Preliminary results of the Lysa Trial. Blood. 2013;122:Abstract 370.

23.

Vose JM. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2013;87:604–9.CrossRef

24.

Weidmann E, Neumann A, Fauth F, Atmaca A, Al-Batran SE, Pauligk C, Jager E. Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol. 2011;22:1839–44.PubMedCrossRef

25.

Horn J, Kleber M, Hieke S, Schmitt-Graff A, Wasch R, Engelhardt M. Treatment option of bendamustine in combination with rituximab in elderly and frail patients with aggressive B-non-Hodgkin lymphoma: rational, efficacy, and tolerance. Ann Hematol. 2012;91:1579–86.PubMedCrossRef

26.

Walter E, Schmitt T, Dietrich S, Ho A, Witzens-Harig M. Rituximab and bendamustine in patients with CD20 + diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy. Leuk Lymphoma. 2013;53:2290–2.CrossRef

27.

Kuntz E, Schmitt T, Dietrich S, Bonn S, Ho A, Witzens-Harig M. Rituximab and bendamustine in patients with diffuse large B-cell lymphoma not eligible for CHOP like chemotherapy. Onkologie. 2010;33:Abstract P173.

28.

Hammarsen J, Sommer M, Gossel C, Teichgraber U, Hahnfeld S, Scholl S, Fricke HJ. Safety and efficacy od bendamustine in patients with agressive non-hodgkin lymphomas (NHL). Blood. 2013;122:Abstract 4371.

29.

Park S, Richards KL, Asch A, Olajide O, Deal AM, Ivanova A. A multicenter phase II study of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma. Blood. 2013;122:Abstract 1791.

30.

Tageja N. Bendamustine: safety and efficacy in the management of indolent non-hodgkins lymphoma. Clin Med Insights Oncol. 2013;5:145–56.

31.

Gafter-Gvili A, Gurion R, Rannani P, Shpilberg O, Vidal L. Bendamustine is not associated with an increase in infections—systematic review and meta-analysis of randomized controlled trials. Blood. 2013;122:Abstract 5125.

32.

McCloskey JK, Broome CM, Cheson BD. Safe and effective treatment of aggressive non-hodgkin lymphoma with rituximab and bendamustine in patients with severe liver impairment. Clin Adv Hematol Oncol. 2013;11:184–8.PubMed

33.

Dewilde S, Woods B, Castaigne JG, Parker C, Dunlop W. Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin’s lymphoma in England and Wales. J Med Econ. 2014;17:111–24.PubMedCrossRef

34.

Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, Banos A, Jaccard A, Park S, Tournilhac O, Schiano de Collela JM, Voillat L, Joly B, Le Gouill S, Saad A, Cony-Makhoul P, Vilque JP, Sanhes L, Schmidt-Tanguy A, Bubenheim M, Houot R, Diouf M, Marolleau JP, Bene MC, Martin A, Lamy T. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol. 2013;31:104–10.PubMedCrossRef

35.

Ponisch W, Mitrou PS, Merkle K, Herold M, Assmann M, Wilhelm G, Dachselt K, Richter P, Schirmer V, Schulze A, Subert R, Harksel B, Grobe N, Stelzer E, Schulze M, Bittrich A, Freund M, Pasold R, Friedrich T, Helbig W, Niederwieser D. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone—a randomized phase III study of the East German study group of hematology and oncology (OSHO). J Cancer Res Clin Oncol. 2006;132:205–12.PubMedCrossRef

36.

Berenson JR, Yellin O, Bessudo A, Boccia RV, Noga SJ, Gravenor DS, Patel-Donnelly D, Siegel RS, Kewalramani T, Gorak EJ, Nassir Y, Swift RA, Mayo D. Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br J Haematol. 2013;160:321–30.PubMedCrossRef

Title: Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma
Authors: Lidia Gil
Maciej Kazmierczak
Renata Kroll-Balcerzak
Mieczyslaw Komarnicki
Publication date: 01-05-2014
Publisher: Springer US
Published in: Medical Oncology / Issue 5/2014
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-014-0944-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2014

Neoadjuvant gemcitabine and carboplatin followed by immediate cystectomy may be associated with a survival benefit in patients with clinical T2 bladder cancer

Overexpression of phosphorylated 4E-binding protein 1 predicts lymph node metastasis and poor prognosis of Chinese patients with hilar cholangiocarcinoma

Safety and efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma: a single center experience

Clinical significance of Wnt-11 and squamous cell carcinoma antigen expression in cervical cancer

Exhaled breath temperature in NSCLC: Could be a new non-invasive marker?

Mantle cell lymphoma harboring Burkitt’s-like translocations presents differential expression of aurora kinase genes compared with others 8q abnormalities

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page